Acurx Pharmaceuticals to Share First Quarter Financial Results
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a clinical stage biopharmaceutical company focused on developing a new class of antibiotics for challenging bacterial infections, is set to discuss its first quarter of 2025 financial results. This conference call will take place on an upcoming Tuesday morning, just before the financial markets open.
Conference Call Details
During this call, David P. Luci, the President and Chief Executive Officer, along with Chief Financial Officer Robert G. Shawah, will host the discussion about the financial performance and the current developments within the company.
Key Information
The pertinent details regarding the conference call include:
- Date: Upcoming Tuesday
- Time: 8:00 AM ET
- Toll-Free Number (U.S.): 1-877-790-1503; Conference ID: 13753625
About Ibezapolstat and Its Development
Acurx is progressing well with ibezapolstat, which is their lead antibiotic candidate. This product is currently gearing up for international Phase 3 clinical trials, targeting patients suffering from C. difficile Infection (CDI). Ibezapolstat stands out as a novel orally administered antibiotic promoting a Gram-positive selective spectrum (GPSS®). Acurx has developed this medication as the first in a new class of DNA polymerase IIIC inhibitors aimed at treating bacterial infections. One remarkable feature of ibezapolstat is its ability to maintain a healthy gut microbiome while effectively targeting C. difficile.
The company has received favorable regulatory guidance recently from European authorities, which supports the advancement of ibezapolstat through the Phase 3 program. Acurx's regulatory pathway is backed by a comprehensive clinical, non-clinical, and Chemistry Manufacturing and Controls (CMC) information package submitted to the regulatory body. They have outlined plans for two international Phase 3 trials, focusing on non-inferiority compared to vancomycin.
Regulatory Designations
Furthermore, ibezapolstat has obtained the Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). This status, which Acurx received back in mid-2018, allows the company to benefit from several incentives aimed at developing new antibiotics under the Generating New Antibiotic Incentives Now (GAIN) Act. Additionally, the FDA granted Fast Track designation for the treatment of CDI in January 2019, highlighting the significance of ibezapolstat's development.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is primarily focused on developing groundbreaking small molecule antibiotics specifically designed to tackle tough bacterial infections. Their innovative approach develops antibiotic candidates that inhibit the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), aiming to stop DNA replication and result in the death of Gram-positive bacteria. This research and development pipeline includes multiple candidates that target Gram-positive bacteria.
To explore more about Acurx Pharmaceuticals and its ongoing projects, more details can be obtained on their official website.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to discuss Acurx's Q1 financial results and provide insights into the company’s latest developments and strategic direction.
What is ibezapolstat?
Ibezapolstat is Acurx's leading antibiotic candidate, set for Phase 3 clinical trials to treat C. difficile Infection, featuring unique properties that maintain gut health while targeting harmful bacteria.
Who will lead the conference call?
David P. Luci, the President and CEO, along with CFO Robert G. Shawah, will lead the conference call and provide updates on the company's progress.
What regulatory designations has ibezapolstat received?
Ibezapolstat has been designated as a Qualified Infectious Disease Product (QIDP) by the FDA and received Fast Track designation for its treatment application.
How can stakeholders learn more about Acurx Pharmaceuticals?
Stakeholders can visit Acurx Pharmaceuticals' official website to gain insights into their product pipeline and overall mission in the biopharmaceutical industry.
